Reversible changes in histone acetylation patterns accompany many important processes in T cells. Eighteen HDACs have been identified in mammalian organisms (
6,
7), and it remains a major scientific challenge to dissect the individual roles for each member of the HDAC family in specific cell lineages and tissues. In this study, we used conditional gene targeting to investigate the role of HDAC1 in T cells. We observed that HDAC1 deletion in T cells enhances allergic airway inflammation by modulating cytokine production in Th1/Th2 effector T cells. Thus, our study indicates a crucial negative regulatory role for HDAC1 in T cells.
One important finding of our study was that T cell-specific loss of HDAC1 leads to enhanced allergic airway inflammation. HDACs were implicated previously in lung inflammation (
23). Patients suffering from chronic obstructive pulmonary disease display reduced HDAC activity and show decreased HDAC2 expression levels in peripheral lung and alveolar macrophages (
35). Reduced HDAC activities and HDAC2 expression were also observed in bronchial biopsies of asthmatic patients (
36). Anti-inflammatory drugs, such as glucocorticoids, reduce inflammation via glucocorticoid receptor-mediated recruitment of HDAC2 and the downregulation of target genes (
37). Thus, reduced expression of HDAC2 in certain lung diseases may increase inflammatory gene expression. In contrast, treatment of patients with the anti-inflammatory drug theophylline increases HDAC activity and, therefore, decreases the inflammatory response in asthma (
38). Our data provide genetic evidence that HDAC1 regulates the extent of the inflammatory response by modulating T cell function. Thus, HDAC1 and HDAC2 may negatively regulate lung disease, although they may act in different cell subsets. Given that HDAC2 is upregulated in HDAC1-deficient T cells, it is possible that the entire impact of HDAC1 loss on airway inflammation is partially masked by increased HDAC2 levels. A partial redundancy of HDAC1 and HDAC2 functions was observed for the control of cardiac morphogenesis (
16), adipogenesis (
39), neuronal development (
40), cell proliferation (
17), and transcription (
41). Whether HDAC2 activity is also important in T cells in controlling the inflammatory response will be an important aspect of future studies. However, the HDAC inhibitor TSA attenuates allergic airway inflammation in mice by reducing T cell infiltration and Th2 cytokine production (
25). In addition, inhibition of the class III HDAC sirtuin 1 leads to attenuated allergic airway inflammation (
26). Thus, other TSA-sensitive and -insensitive members of the HDAC family that may be expressed in T cells, as well as in other cell types (e.g., alveolar macrophages), are involved in the pathophysiology of allergic airway inflammation.
The differentiation of CD4
+ T cells into Th1 or Th2 effector cells is a complex process that is accompanied by several epigenetic changes at the
Ifng and
Il4 cytokine loci (
3). TCR/CD28-mediated triggering of CD4
+ T cells leads to a rapid increase in histone acetylation at the
Ifng and
Il4 cytokine loci and low-level, unbiased transcription of IL-4 and IFN-γ (
30,
31). Subsequently, cytokine signaling and the activities of the transcriptional regulators T-bet and GATA-3 are required to increase and maintain lineage-specific epigenetic modification at the
Ifng and
Il4 loci, respectively, to allow high-level lineage-specific Th1 and Th2 cytokine expression. In parallel, histone acetylation of the lineage-inappropriate cytokine loci decreases in the presence of the polarizing cytokines, leading, together with de novo DNA methylation, to complete transcriptional silencing (
3,
5). Therefore, the increase in lineage-specific cytokine expression in lung CD4
+ T cells in
Hdac1Δ mice and in HDAC1-deficient Th1 and Th2 cells indicates an essential role for HDAC1 in controlling cytokine-expression levels in differentiated effector T cells. Our finding is substantiated by a recent study showing a genome-wide association of HDAC1 with promoters of active genes in CD4
+ T cells, suggesting that HDAC1 fine-tunes gene expression instead of keeping silent genes repressed (
42). We observed increased expression of IL-4 already at day 3 in Th2-polarizing cultures. Thus, the demonstration that HDAC1 bound to the
Il4 gene locus in nonactivated naive CD4
+ T cells suggests a critical role for HDAC1 during the early phase of effector differentiation in restricting cytokine transcription to low levels. In support of our data, it was shown that treatment of differentiating T cells with the HDAC inhibitor butyrate resulted in increased numbers of IL-4–expressing differentiating CD4
+ effector cells reminiscent of activated, differentiated HDAC1-deficient cells (
20). This indicates that HDAC1 might be the major HDAC regulating the epigenetic status of the activated cytokine loci, thus ensuring appropriate levels of the respective cytokines, although we cannot rule out that HDAC1 influences cytokine expression indirectly (e.g., by changing the expression of an important transcription factor that controls the Th2 cytokine locus). Moreover, the finding of increased Th2 cytokine levels in vivo provides an explanation for the enhanced clinical parameters in the allergic airway inflammation model in conditional HDAC1-deficient mice.
In agreement with other studies (
20,
32), we observed that cytokines were expressed only in those cell subsets that have undergone several rounds of cell division. This may imply that cell proliferation is required to remove other repressive epigenetic marks, such as DNA methylation, from the Th2 cytokine loci. The enhanced IL-4 production in HDAC1-deficient Th2 cells partially resembles the phenotype of T cells deficient for the methyl CpG-binding domain protein-2 (MBD2) (
32) or of DNA methyltransferase 1-deficient T cells (
18). MBD2 was suggested as a potential link between DNA methylation and silent chromatin (
43). Further, MBD2 was shown to interact with a HDAC1 corepressor complex (
44), thus also providing a potential link between DNA methylation and histone deacetylation. In contrast to HDAC1-deficient CD4
+ T cells,
Mbd2−/− CD4
+ T cells show aberrant expression of IL-4 in activated T cells that have not yet divided, and
Mbd2−/− Th1 cells produce significant amounts of IL-4 (
32). Thus, despite increased levels of cytokine expression in MBD2- and HDAC1-deficient CD4
+ T cells, only the loss of MBD2 triggers lineage-inappropriate cytokine expression. This suggests a functional hierarchy of HDAC1 and MBD2 in the regulation of the Th2-cytokine loci.
Taken together, our study provides genetic evidence that HDAC1 activity in T cells regulates the extent of allergic airway inflammation. Moreover, our data show that activation of the Th1 and Th2 cytokine loci is counterbalanced by HDAC1, indicating a specific role for HDAC1 in modulating the cytokine-expression program during effector differentiation. This may indicate a potential therapeutic usage of specific HDAC1 inhibitors in clinical settings that require enhanced immune responses and inflammation.